Analyst Ratings For NASDAQ:ZIOP – Ziopharm Oncology (NASDAQ:ZIOP)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:ZIOP – Ziopharm Oncology (NASDAQ:ZIOP) with a price target of $5.50.
Some recent analyst ratings include
- 5/14/2018-HC Wainwright Reiterated Rating of Buy.
- 12/11/2017-Raymond James Reiterated Rating of Hold.
- 2/28/2017-Griffin Securities Reiterated Rating of Buy.
- 1/12/2017-JPMorgan Chase Reiterated Rating of Hold.
- 8/10/2016-Wells Fargo Upgrade from a “Underperform ➝ Market Perform” rating to a “” rating.
- 7/18/2016-Mizuho Reiterated Rating of Neutral.
Recent Insider Trading Activity For NASDAQ:ZIOP – Ziopharm Oncology (NASDAQ:ZIOP)
NASDAQ:ZIOP – Ziopharm Oncology (NASDAQ:ZIOP) has insider ownership of 10.40% and institutional ownership of 40.12%.
- On 11/8/2017 David M Md Mauney, EVP, bought 4,270 with an average share price of $4.68 per share and the total transaction amounting to $19,983.60.
- On 11/8/2017 Laurence James Neil Cooper, CEO, bought 6,440 with an average share price of $4.68 per share and the total transaction amounting to $30,139.20.
- On 6/4/2015 Murray Brennan, Director, sold 40,000 with an average share price of $9.70 per share and the total transaction amounting to $388,000.00.
- On 2/9/2015 Randal J Kirk, Director, bought 1,440,000 with an average share price of $8.75 per share and the total transaction amounting to $12,600,000.00.
- On 10/29/2013 Randal J Kirk, Director, bought 2,857,143 with an average share price of $3.50 per share and the total transaction amounting to $10,000,000.50.
Recent Trading Activity for NASDAQ:ZIOP – Ziopharm Oncology (NASDAQ:ZIOP)
Shares of NASDAQ:ZIOP – Ziopharm Oncology closed the previous trading session at 4.32 down -0.05 1.26% with 4.369999885559082 shares trading hands.